PT  - JOURNAL ARTICLE
ED  - Haller, Hermann
TI  - Olmesartan Reduces Microalbuminuria in Patients with Type 2 Diabetes
DP  - 2010 Nov 01
TA  - MD Conference Express
PG  - 9--10
VI  - 10
IP  - 5
4099  - http://mdc.sagepub.com/content/10/5/9.2.short
4100  - http://mdc.sagepub.com/content/10/5/9.2.full
AB  - Early treatment with the angiotensin receptor blocker (ARB) olmesartan significantly reduced the risk of developing microalbuminuria among patients with type 2 diabetes, according to new interim findings from the ongoing Randomized Olmesartan and Diabetes Microalbuminuria Prevention [ROADMAP] trial. However, olmesartan also appeared to increase the risk of cardiovascular mortality, raising concerns about the safety of ARBs in this patient population.